Invokana Diabetic Ketoacidosis Lawsuit Filed in California Federal Court, Bernstein Liebhard LLP Reports
"Our Firm has heard from a number of individuals who allegedly developed ketoacidosis due to their use of Invokana and other SGLT2 inhibitor diabetes drugs. As we continue to investigate these claims, we will monitor this matter closely," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating product liability claims on behalf of Type 2 diabetes patients who were hospitalized following a diagnosis of diabetic ketoacidosis, allegedly due to their use of SGLT2 inhibitors.
Invokana and Diabetic Ketoacidosis
SGLT2 inhibitors lower blood glucose levels by facilitating the removal of glucose via the kidneys. Launched in March 2013, Invokana was the first SGLT2 inhibitor to be approved for the treatment of Type 2 diabetes. Other medications in this class include Invokamet, Farxiga, Xigduo XR, Jardiance, and Glyxambi.
Diabetic ketoacidosis, also known as acidosis, ketoacidosis, or ketosis, is a potentially life-threatening condition that can lead to diabetic coma or death. The condition occurs when toxic blood acids called ketones accumulate in the blood. In May 2015, the U.S. Food & Drug Administration (FDA) announced that it was investigating 20 reports of diabetic ketoacidosis in patients taking SGLT2 inhibitors to determine whether changes are needed in the prescribing information for this class of medications. The incidents which prompted the FDA to act all occurred from March 2013 to June 6, 2014. However, the agency also acknowledged that additional reports have been received since June 2014. The FDA has advised SGLT2 inhibitor patients to seek medical attention immediately if they experience difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness.
Type 2 diabetes patients who were hospitalized for diabetic ketoacidosis while using Invokana or another SGLT2 inhibitor medication may be entitled to compensation for medical bills and other related damages. To learn more about filing an Invokana lawsuit, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP